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ders characterized by retinal ganglion cell (RGC) death,
such as prematurity-induced retinal degeneration, glau-
coma, and age-related macular degeneration. In all these
disorders excitotoxicity is a prominent component of neu-
ronal damage, but clinical data discourage the development
of NMDA receptor antagonists as neuroprotectants. Here,
we show that activation of mGlu1 metabotropic glutamate
receptors largely contributes to excitotoxic degeneration
of RGCs. Mice at postnatal day 9 were challenged with a
toxic dose of monosodium glutamate (MSG, 3 g/kg), which
caused the death of >70% of Brn-3a+ RGCs. Systemic
administration of the mGlu1 receptor negative allosteric
modulator (NAM), JNJ16259685 (2.5 mg/kg, s.c.), was largely
protective against MSG-induced RGC death. This treatment
did not cause changes in motor behavior in the pups. We
also injected MSG to crv4mice, which lack mGlu1 receptors
because of a recessive mutation of the gene encoding the
mGlu1 receptor. MSG did not cause retinal degeneration in
crv4 mice, whereas it retained its toxic activity in their
wild-type littermates. These findings demonstrate that
mGlu1 receptors play a key role in excitotoxic degeneration
of RGCs, and encourage the study of mGlu1 receptor NAMs
in models of retinal neurodegeneration.  2017 IBRO. Pub-
lished by Elsevier Ltd. All rights reserved.http://dx.doi.org/10.1016/j.neuroscience.2017.09.005
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Retinal ganglion cells (RGCs) collect the visual
information from photoreceptors via bipolar and
amacrine cells, and transfer the information to the brain
through the optic nerve. Excitotoxic degeneration of
RGCs play a role in the pathophysiology of retinal
disorders, such as glaucoma (Lipton, 2003; Seki and
Lipton, 2008), age-related macular degeneration, and
prematurity-induced retinal degeneration (Hinton et al.,
1986; Tenhula et al., 1992; Lipton, 2003; Casson, 2006;
Kaur et al., 2008; Seki and Lipton, 2008; Herna´ndez
and Simo´, 2012). It is generally believed that glutamate-
induced RGC damage is mediated by the activation of
N-methyl-D-aspartate (NMDA) receptors and the resulting
increase in intracellular Ca2+ (Ferreira et al., 1996; Niwa
et al., 2016). However, the value of NMDA receptors as
candidate drug targets for retinal neuroprotection was
questioned by the disappointing clinical data with the
NMDA channel blocker, memantine, in the treatment of
glaucoma (Chidlow et al., 2007; Osborne, 2009). The lack
of efficacy of memantine might reflect the opposite role of
synaptic and extrasynaptic NMDA receptors in mecha-
nisms of neurodegeneration/neuroprotection (reviewed
by Hardingham and Bading, 2010). Alternatively, gluta-
mate receptor types other than NMDA receptors may con-
tribute to excitotoxic retinal degeneration.
Group-I metabotropic glutamate receptors (mGlu1
and mGlu5 receptors) are linked to NMDA receptors
through a chain of anchoring proteins, and their
activation enhances NMDA receptor function (Tu et al.,
1999; Awad et al., 2000). mGlu1 and mGlu5 receptors
are coupled to Gq/11. Their activation stimulates polyphos-
phoinositide (PI) hydrolysis, a transduction mechanism
that leads to increased intracellular free Ca2+ and activa-
tion of protein kinase C (Nicoletti et al., 2011). Both effects
might contribute to neuronal degeneration under patho-
logical conditions. The role of mGlu1 and mGlu5 recep-
tors in mechanisms of neurodegeneration/
neuroprotection is discussed in numerous review articles
(Nicoletti et al., 1999; Bruno et al., 2001, 2017).
In the retina, mGlu1 and mGlu5 receptors are present
in ON-bipolar and amacrine cells. In addition, mGlu1
receptors are also found in RGCs (Koulen et al., 1997;
Brandsta¨tter et al., 1998; Yang, 2004). We found recently
that mGlu1, but not mGlu5, receptors are coupled to PI
hydrolysis in the mouse and bovine retina (Romano
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tions, mGlu1 receptors might be involved in mechanisms
of retinal degeneration. We tested this hypothesis using
the monosodium glutamate (MSG) model of retinal
degeneration, which is a milestone in the field of excito-
toxicity offering one of the first demonstrations that exces-
sive glutamate can be toxic to neurons. The model is
based on systemic administration of MSG to pups in the
first 9–10 days of postnatal life, when the blood–brain bar-
rier and the blood–retina barriers are not yet fully devel-
oped. At postnatal day (PND)9/10 systemic MSG
causes a severe retinal damage involving not only gan-
glion neurons, but also cells of the inner nuclear layer.
MSG is less efficient in causing retinal degeneration at
earlier postnatal days, and does not cause significant reti-
nal damage at PND> 11 even at sublethal doses (Blood
et al., 1969; Olney, 1969; Lowe et al., 1970). Using both
genetic and pharmacological approaches, we now
demonstrate that activation of mGlu1 receptors largely
contributes to MSG-induced RGC death. As a pharmaco-
logical approach we treated mice systemically with com-
pound JNJ16259685, a highly selective negative
allosteric modulator (NAM) of mGlu1 receptors which
blocks receptor function regardless of the concentrations
of ambient glutamate (Lavreysen et al., 2004).EXPERIMENTAL PROCEDURES
Animals
C57BL/6J mice (Charles River, Calco, Italy), crv4 mice
and their Balb/c wild-type littermates (provided by A.P.)
were used in this study. crv4 mice have a spontaneous
recessive mutation consisting of a retrotransposon long
terminal repeat (LTR) insertion that disrupts the splicing
of the Grm1 gene determining the absence of the
mGlu1 receptor protein (Conti et al., 2006). crv4 mice
were generated by heterozygous breeding. Mouse geno-
typing was performed in DNA extracts from the mouse tail
as reported previously (Conti et al., 2006). Pregnant dams
had free access to food and water and were maintained in
cages in an environmentally controlled room with a tem-
perature of 22 C, a humidity of 55%, and a 12-h light/dark
cycle. The offspring was used at PND9, with no sex
distinction.
We made all efforts to reduce the number of animals.
Experiments were performed in conformity with the
Statement for the Use of Animals in Ophthalmic and
Vision Research and with the Italian law on Animal Care
No. 26/2014 and the Directive 2010/63/EU. The study
was approved by the local Animal Care and Use
Committee of Neuromed Institute.Experimental design
For toxicity experiments, C57BL/6J mice at PND9
(n= 3–9 mice per group) were treated as follows. Two
groups received a subcutaneous (s.c.) injection of corn
oil (Sigma–Aldrich, Milan, Italy), followed, 30 min later,
by s.c. injection of either saline or MSG (3 g/kg; Sigma–
Aldrich); two additional groups were treated with 3,4-
dihydro-2 H-pyrano[2,3-b]quinolin-7-yl-(cis-4-methoxycyclohexyl)-methanone (JNJ16259685; Tocris Bioscience,
Bristol, UK), dissolved in corn oil (2.5 mg/kg) followed,
30 min later, by a s.c. injection of either saline or MSG.
In another set of experiments, four groups of crv4 mice
or their wild-type littermates (n= 5–7 mice per group)
were injected s.c. with either saline or MSG (3 g/kg).
Homozygous crv4 and wild-type mice were genotyped
prior to the experiment.
For behavioral analysis, two groups of 4 C57BL/6J
mice at PND9 were treated s.c. with a single injection of
either JNJ16259685 (2.5 mg/kg) or its vehicle.
Behavioral analysis was performed 30 min and 18 h
after injections. A total number of 59 mice were used in
the study.Immunohistochemical analysis and RGC counting
All mice were killed 18 h after drug injection. The eyes and
cerebella were quickly removed. Cerebella were stored at
80 C and then used for immunoblot analysis of mGlu1a
receptors (see below). Eyes were placed in 4% (w/v)
paraformaldehyde for 5 h at 4 C. After extensive
washing in water for 5 min, eyes were placed in 70%
ethanol at 4 C until paraffin inclusion.
Retinal sections (20 mm)were incubated overnight with
polyclonal goat anti-Brn-3a antibody (1:100; sc-6026,
Santa Cruz Biotechnology Inc., Dallas, TX, USA), for 1 h
with secondary biotin-coupled anti-goat antibody (1:200;
BA 9005, Vector Laboratories, Burlingame, CA, USA)
and then for 1 h with Horseradish Peroxidase
Streptavidin (1:100; SA-5004, Vector Laboratories).
3,3-diaminobenzidine tetrachloride (Sigma–Aldrich) was
used for detection. Before incubation with primary
antibody, sections were treated with citrate buffer, and
heated in a microwave for 15 min for antigen retrieval.
Negative control was performed without primary antibody.
Neuronal density values (number of neurons/mm2)
were calculated in retinal tissue slides stained with Brn-
3a (sc-6026, Santa Cruz Biotechnology Inc.). Cells were
counted at 100 magnification within a square area
(disector), of 2500 lm2 (50  50 lm). Cell counting was
performed by an operator (D.B.) who was unaware of
the treatments or mouse genotypes. The disectors were
positioned within an area of interest (AOI) over the
ganglion cell layer of the retinal slides. This AOI, hand-
drawn by the operator, consistently started about
800 lm laterally to the emergence of the optic nerve.
Within this area, the software (Image Pro Plus 6.2,
Media Cybernetics, Inc.) randomly puts a series of
disectors where ganglion cells were counted at high
magnification (100). The results were expressed as
number of cell density per mm2.
Measurements of cell number were not extended to
other neuronal types of the retina (e.g., neurons of the
inner nuclear layer) that could have been damaged by
MSG administration (Olney, 1969).Confocal microscopy analysis of mGlu1a receptors
in the retina
For immunofluorescence analysis, 30-lm retinal sections
were incubated with a mouse anti-mGlu1 primary
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sections were then incubated with a secondary antibody
conjugated to Alexa Fluor 488 (1:200, Invitrogen,
Carlsbad, CA, USA). Slides were coverslipped with
mounting medium (Vector). Tissue sections were
scanned using a LSM 5 Pascal confocal laser scanning
microscope with a Zeiss ECPLAN-NEOFLUAR
40/1.30 M27 oil immersion objective (Carl Zeiss
Microimaging Inc.). We used a 488-nm argon laser to
excite Alexa Fluor 488.Western blot analysis of mGlu1a receptors in crv4
and wild-type mice
Immunoblot analysis of mGlu1a receptors was carried in
the cerebellum of crv4 mice and their wild-type
littermates as reported previously (Romano et al., 2016)
using a mouse monoclonal anti-mGlu1a antibody
(1:700, BD Biosciences).Behavioral analysis
Analysis of motor behavior in PND9 pups treated with
JNJ16259685 (2.5 mg/kg, s.c.) or its vehicle was
performed as described by Feather-Schussler and
Ferguson (2016).
All behavioral tests were performed 30 min and 18 h
after injections, i.e., at 4.00 p.m. and 9.00 a.m. of the
following day, respectively. The battery of motor tests
included: (i) a 3-min ambulation test, in which the
spontaneous motor activity of mice was scored as
follows: 0 = absence of movements; 1 = crawling
associated with asymmetric limb movements;
2 = symmetric but slow limb movements; and, 3 = fast
movements; (ii) a righting reflex test, in which pups
were placed on their backs and the time needed to turn
over was recorded; (iii) a hindlimb suspension test, in
which pups were placed vertically by their hind limbs
inside a 50-ml plastic tube and hindlimb posture was
scored as follows: 4 = hindlimb separation with a raised
tail; 3 = hindlimbs are close to each other but they are
still separated; 2 = hindlimbs are close and frequently
touch each other; 1 = constant clasping of the
hindlimbs with a raised tail; and 0 = persistent hindlimb
clasping with a lowered tail; and (iv) a grip strength test
used for the evaluation of grasp-reflex strength, in which
mice were placed on a metal grid that was tilted slowly
from horizontal to vertical position recording the angle of
the grid when pups fell down.Statistical analysis
Data are presented as medians and all individual data
points in Fig. 1, and as means ± S.E.M. in Fig. 2 and
Fig. 4. Statistical analysis of data shown in Fig. 1 was
performed using the non-parametric Kruskal–Wallis test.
Dunn’s Multiple Comparison test was used to isolate the
differences. Statistical analysis of data presented in
Fig. 2 was performed by Student’s t-test (t values are
reported in the Results section and in the
Figure legend). Statistical analysis of data shown in
Fig. 4 was performed by a One-way ANOVA (F valuesare reported in the Results section and in the
Figure legend); the Neumann–Keuls test was used as a
post hoc test to isolate the differences. A p
value < 0.05 was considered as statistically significant.
RESULTS
Pharmacological blockade of mGlu1 receptors is
protective against MSG-induced neuronal death in
the mouse retina
We performed immunohistochemical analysis using
antibodies directed toward Brn-3a, a reliable marker
for the identification and quantification of RGCs
(Nadal-Nicola´s et al., 2009). Accordingly, Brn-3a
immunostaining was confined to RGCs and was not
observed in other retinal layers (Figs. 1 and 4).
A single systemic injection of MSG (3 g/kg) to PND9
C57BL/6J mice caused extensive retinal degeneration
reducing the number of Brn-3a+ RGCs by >70% with
respect to control mice treated with saline (Kruskal–
Wallis’ non parametric test and Dunn’s Multiple
Comparison test; H3 = 20.063; p< 0.001) (Fig. 1A, B).
Pre-treatment with the selective mGlu1 receptor NAM,
JNJ16259685 (2.5 mg/ kg), reduced the damaging effect
of MSG on retinal ganglion cells. In mice treated with
MSG combined with JNJ16259685 the number of RGC
was reduced by only <20%, and the resulting value
was not significantly different from values obtained in all
other groups of mice, including control mice.
JNJ16259685 alone had no effect on RGC number
(Kruskal–Wallis’ non parametric test and Dunn’s Multiple
Comparison test) (Fig. 1A, B). These data suggest that
activation of mGlu1 receptors largely contribute to
excitotoxic RGC damage.
Evaluation of motor behavior in mice treated with
JNJ16259685
To examine whether pharmacological blockade of mGlu1
receptors could affect motor behavior in PND9 pups, we
used a battery of four behavioral tests that evaluate
spontaneous motor activity, hindlimb posture, muscular
strength, and the righting reflex (Feather-Schussler and
Ferguson, 2016). At short time intervals after injection
(30 min), systemic treatment with JNJ16259685 (2.5 mg/
kg, s.c.) did not cause significant changes in the ambula-
tion score, hindlimb suspension score, and the grip
strength test, and righting reflex (Student’s t-test;
t6 = 1.492) (Fig. 2A). At 18 h after the treatment, no major
changes in motor behavior were seen in mice receiving
JNJ1629685, with the exception of a small but significant
increase in the mouse performance in the grip strength
test (Student’s t-test; t6 = 2.771; p= 0.032) (Fig. 2B).
MSG-induced retinal damage is attenuated in mice
lacking mGlu1 receptors
To confirm a role for mGlu1 receptors in mechanisms of
excitotoxic retinal degeneration, we used crv4 mice and
their wild-type littermates. The absence of mGlu1
receptor protein in crv4 mice was further demonstrated
by Western blot analysis of mGlu1a receptor protein in
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Fig. 1. Effect of systemic pharmacological blockade of mGlu1 receptors on MSG-induced RGC
damage. Representative images of Brn-3a+ RGCs of mice treated s.c. with vehicle + saline,
JNJ16259685 (2.5 mg/kg) + saline, vehicle + MSG (3 g/kg), and JNJ16259685 + MSG are
shown in (A). Cell counts are shown in (B) as medians and all individual data points of 3–9 retinas
per group (one retina per individual mouse). The equal variance parameter of a one-way ANOVA
failed in the analysis perhaps owing to the limited size of the group treated with JNJ16259685
alone (n= 3). Thus, we used the non-parametric Kruskal–Wallis test followed by Dunn’s Multiple
Comparison test for statistical analysis (H3 = 20.063; p< 0.001). Values obtained in mice treated
with MSG alone (*) were significantly different with respect to values obtained in control mice
(p< 0.001) or in mice treated with JNJ16259685 alone (p< 0.05). Values obtained in mice
treated with MSG combined with JNJ16259685 did not significantly differ from data obtained in all
other groups of mice. Treatment with JNJ16259685 alone had no significant effect on RGC counts
with respect to control mice.
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expressed at high levels (Nicoletti et al., 2011). Immuno-
blots of mGlu1a receptor protein showed the expected
band at 140 kDa corresponding to receptor monomers,
and a higher molecular size band, corresponding to
receptor dimers (Fig. 3A). The mGlu1a receptor was
absent in the cerebellum of crv4 mice, as expected
(Fig.3A). We also examined mGlu1a receptor immunore-
activity in the retina of wild-type and crv4mice by confocal
analysis. In wild-type mice, mGlu1a immunoreactivity was
detected in the RGCs and inner plexiform layers (Fig.3B)
in agreement with previous reports (Koulen et al., 1997;
Dhingra and Vardi, 2012). mGlu1a immunoreactivity
was not detected in the retina of crv4 mice (Fig. 3B).
There was no difference in RGC number between crv4
mice and their wild-type littermates (Fig. 4A, B). MSG
administration to wild-type Balb/c littermates reduced
RGC number to a lower extent than in C57BL/6J mice
(compare Fig. 4 with Fig. 1), but the reduction was still
highly significant (One-way ANOVA+ Neumann–Keuls’
post-hoc test; F3,22 = 5.031; p< 0.05), indicating that
excitotoxic retinal damage is strain-dependent. MSG-
induced RGC degeneration was abolished in crv4 mice
(p< 0.05; Fig. 4A, B), confirming that, at least in the
MSG model, activation of mGlu1 receptors is necessary
for the induction/development of excitotoxic retinal
damage.DISCUSSION
Our data suggest that mGlu1
receptors are recruited in
mechanisms of excitotoxic retinal
degeneration and their activation is
necessary for MSG-induced RCG
death. This could not be
automatically inferred from our
knowledge of mGlu1 receptor
signaling because the existing data
on mGlu1 receptors and
neurodegeneration are controversial.
Most of the studies carried out in
in vitro or in vivo models have shown
a neuroprotective activity of mGlu1
receptor antagonists against
excitotoxic or hypoxic/ischemic
neuronal death (Bruno et al., 1999;
Pellegrini-Giampietro et al., 1999;
Battaglia et al., 2001; De Vry et al.,
2001; Cozzi et al., 2002; Meli et al.,
2002; Moroni et al., 2002; Murotomi
et al., 2008, 2010; Smialowska et al.,
2012; Li et al., 2013). However,
mGlu1 receptor knockout mice were
as vulnerable as their wild-type coun-
terparts to focal cerebral ischemia
and kainate-induced neurotoxicity
(Ferraguti et al., 1997), and pharma-
cological activation of mGlu1 recep-
tors was found to protect motor
neurons against kainate-induced toxi-city (Valerio et al., 2002). Thus, mGlu1 receptors can be
either neurotoxic or neuroprotective depending upon the
cellular context and the experimental paradigm of neuro-
toxicity. For example, Michel Baudry and his colleagues
have shown that mGlu1 receptors may activate either a
neuroprotective signal (the phosphatidylinositol-3-kinase
pathway) or a toxic signal (intracellular Ca2+ release),
and the concomitant activation of NMDA receptors shifts
the balance toward the neurotoxic signal (Xu et al.,
2007; Zhou et al., 2009). In cultured neurons, mGlu1
receptors behave as a «dependence receptors», support-
ing cell survival in response to agonist activation, and
causing apoptotic death in the absence of glutamate
(Pshenichkin et al., 2008). Another variable is the
heterodimerization of mGlu1 receptors with mGlu5 recep-
tors (Doumazane et al., 2011), which are also coupled to
PI hydrolysis and have a dual role in mechanisms of neu
rodegeneration/neuroprotection (Nicoletti et al., 1999).
At least the latter component is absent in the retina,
where only mGlu1 receptors appear to be coupled to PI
hydrolysis (with the detection limits of the PI assay).
Accordingly, using both bovine retinal slices and intact
mouse retinas, we were able to demonstrate that
stimulation of PI hydrolysis by the mGlu1/5 receptor
agonist, 3,5-dihydroxyphenylglycine (DHPG), was
sensitive to mGlu1 receptor blockade, but was not
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Fig. 2. Effect of JNJ16259685 treatment on motor behavior in PND9 pups. The effect of systemic JNJ16259685 treatment (2.5 mg/kg, s.c.) on
spontaneous motor activity (ambulation score), hindlimb posture (hindlimb suspension (HLS) score), grip strength test (inverted angle), and righting
reflex (righting time) at 30 min and 18 h after injection is shown in (A) and (B), respectively. Values are means ± S.E.M. of 4 mice per group.
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Fig. 3. Lack of mGlu1 receptors in the cerebellum and retina of crv4 mice used for toxicity
experiments. Western blot analysis of mGlu1a receptor protein in the cerebellum of wild-type
littermates of Balb/c strain and crv4 mice is shown in (A). The representative immunoblot
(n= 4–5 per group) shows the absence of mGlu1a receptor in crv4 mice, as expected.
Representative confocal images of mGlu1a receptor protein in the retina of crv4 mice and their
wild-type littermates of Balb/c strain are shown in (B). mGlu1a receptor expression in C57BL/6J
mice is also shown for comparison. Note that in wild-type mice mGlu1a receptor immunore-
activity was mainly detected in the ganglion cell layer (GCL), and that no immunoreactivity was
detected in crv4 mice.
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blockade. In addition, we found no
PI response to DHPG in retinas of
crv4 mice lacking mGlu1 receptors,
whereas the response was intact in
retinas of mGlu5 receptor knockout
mice (Romano et al., 2016). Thus,
the retina offers a unique example of
a tissue in which the PI response to
DHPG is exclusively mediated by
mGlu1 receptors. Our present find-
ings indicate that mGlu1 receptors
are key players in mechanisms of
RGC degeneration triggered by toxic
concentrations of glutamate. In the
interpretation of data obtained after
systemic treatment with
JNJ16259685 we cannot exclude that
the drug was protective by blocking
mGlu1 receptors outside the retina.
However, this is unlikely because, at
least to our knowledge, brain struc-
tures that express significant levels
of mGlu1 receptors (e.g., the cerebel-
lum, thalamus, olfactory bulb, and hip-
pocampal dentate gyrus) do not send
projections to the retina. We could not
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Fig. 4. crv4 mice lacking mGlu1a receptors are protected against MSG-induced RGC damage.
Representative images of Brn-3a+ RGCs of wild-type and crv4 mice treated s.c. with vehicle or
JNJ16259685 (2.5 mg/kg) are shown in (A). Cell counts are shown in (B), where values are
means + S.E.M. of 5–7 retinas per group (one retina per individual mouse). *p< 0.05 (One-way
ANOVA+ Neumann–Keuls’ post hoc test) vs. all other groups. One-way ANOVA: F3,22 = 5.03;
p= 0.0083.
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of pups for a series of technical reasons. For example,
eyelids are still closed at PND9 in mice, and intravitreal
injections require a surgical cut of the eyelid. In addition,
the whole procedure requires deep anesthesia, which is
expected to have a significant impact on the study of
the role played by a glutamate receptor (the mGlu1 recep-
tor) in excitotoxic retinal degeneration. Our findings have
potential translational value in the treatment of
prematurity-induced retinal damage, in which excitotoxic-
ity largely contributes to the pathophysiology of RGC
death (see Introduction and References therein). Pituitary
adenylyl cyclase activating peptide (PACAP) and the
potassium channel activator, diazoxide, have shown neu-
roprotective activity in the MSG model in rats (Tama´s
et al., 2004; Ra´cz et al., 2007; Atlasz et al., 2007,
2008). However, both compounds were tested after
intravitreal administration, and whether systemic adminis-
tration of PACAP or diazoxide may confer neuroprotec-
tion against retinal damage is unknown. JNJ16259685
shows central bioavailability in rodents (Lavreysen et al.,
2004), and, because of its hydrophobicity, is expected
to cross the blood–retina barrier and reach sufficient con-
centrations to achieve neuroprotection in the developing
human retina. By definition, NAMs bind to an allosteric
region of mGlu1 receptors, and, therefore, they inhibit
mGlu1 receptor activation regardless of the ambient con-
centrations of glutamate. Thus, JNJ16259685 and other
mGlu1 receptor NAMs might be potential candidates for
the treatment of prematurity-induced retinal degeneration.
From a therapeutic perspective, it was important to exam-
ine the effect of systemic treatment with JNJ16259685 on
motor behavior in PND9 mice. Interestingly, the drug did
not cause detectable abnormalities in motor function after30 min and 18 h, and even improved
the performance in the grip strength
test at 18 h. This was unexpected
because mGlu1 receptor blockade is
known to impair motor learning and
motor coordination, two functions that
are mediated by mGlu1 receptors
expressed by cerebellar Purkinje cells
(Aiba et al., 1994; Conquet et al.,
1994; Ichise et al., 2000; Ohtani
et al., 2014; Kano and Watanabe,
2017). However, mGlu1 receptors
are still expressed at low levels in
the cerebellum of PND9 mice, and
begin to control cerebellar maturation
and function after PND12 (reviewed
by Kano and Watanabe, 2017). The
developmental pattern of expression
of mGlu1 receptors in the human
cerebellum is unknown, and, there-
fore, we cannot exclude that the use
of mGlu1 receptor NAMs for the treat-
ment of prematurity-induced retinal
degeneration may have an impact on
motor learning and motor perfor-
mance in humans.
Our data also encourage the study
of mGlu1 receptor NAMs as potentialdisease modifiers in the treatment of glaucoma and
other chronic neurodegenerative disorders of the retina.
The study, however, requires a chronic systemic
treatment with mGlu1 receptor NAMs, which, in this
case, might have negative consequences on motor
learning and motor coordination by restraining the
activity of mGlu1 receptors in cerebellar Purkinje cells
(Aiba et al., 1994; Conquet et al., 1994; Ichise et al.,
2000; Ohtani et al., 2014; Kano and Watanabe, 2017).
Thus, accurate pharmacological studies in experimental
animal models of glaucoma and other degenerative eye
disorders are needed to establish whether mGlu1 recep-
tor blockade might be considered as a valuable and safe
strategy to slow the progression of these disorders.
CONFLICT OF INTEREST
The authors do not have any conflict of interest.
REFERENCES
Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, Zwingman
TA, Tonegawa S (1994) Deficient cerebellar long-term depression
and impaired motor learning in mGluR1 mutant mice. Cell
79:377–388.
Atlasz T, Babai N, Kiss P, Reglodi D, Tama´s A, Szabadfi K, To´th G,
Hegyi O, Lubics A, Ga´briel R (2007) Pituitary adenylate cyclase
activating polypeptide is protective in bilateral carotid occlusion-
induced retinal lesion in rats. Gen Comp Endocrinol 153:108–114.
Atlasz T, Szabadfi K, Kiss P, Babai N, Koszegi Z, Tamas A, Reglodi
D, Gabriel R (2008) PACAP-mediated neuroprotection of
neurochemically identified cell types in MSG- induced retinal
degeneration. J Mol Neurosci 36:97–104.
Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of
metabotropic glutamate receptor 5 has direct excitatory effects
148 F. Liberatore et al. / Neuroscience 363 (2017) 142–149and potentiates NMDA receptor currents in neurons of the
subthalamic nucleus. J Neurosci 20:7871–7879.
Battaglia G, Bruno V, Pisani A, Centonze D, Catania MV, Calabresi
P, Nicoletti F (2001) Selective blockade of type-1 metabotropic
glutamate receptors induces neuroprotection by enhancing
gabaergic transmission. Mol Cell Neurosci 17:1071–1083.
Blood FR, Oser BL, White PL, Olney JW (1969) Monosodium
glutamate. Science 165:1028–1029.
Brandsta¨tter JH, Koulen P, Wa¨ssle H (1998) Diversity of glutamate
receptors in the mammalian retina. Vision Res 38:1385–1397.
Bruno V, Battaglia G, Kingston A, O’Neill MJ, Catania MV, Di Grezia
R, Nicoletti F (1999) Neuroprotective activity of the potent and
selective mGlu1a metabotropic glutamate receptor antagonist,
(+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison
with LY357366, a broader spectrum antagonist with equal affinity
for mGlu1a and mGlu5 receptors. Neuropharmacology
38:199–207.
Bruno V, Battaglia G, Copani A, Cespe´des VM, Galindo MF, Cen˜a V,
Sa´nchez-Prieto J, Gasparini F, Kuhn R, Flor PJ, Nicoletti F (2001)
An activity-dependent switch from facilitation to inhibition in the
control of excitotoxicity by group I metabotropic glutamate
receptors. Eur J Neurosci 13:1469–1478.
Bruno V, Caraci F, Copani A, Matrisciano F, Nicoletti F, Battaglia G
(2017) The impact of metabotropic glutamate receptors into active
neurodegenerative processes: a ‘‘dark side” in the development of
new symptomatic treatments for neurologic and psychiatric
disorders. Neuropharmacology 115:180–192.
Casson RJ (2006) Possible role of excitotoxicity in the pathogenesis
of glaucoma. Clin Exp Ophthalmol 34:54–63.
Chidlow G, Wood JP, Casson RJ (2007) Pharmacological
neuroprotection for glaucoma. Drugs 67:725–759.
Conquet F, Bashir ZI, Davies HC, Daniel H, Ferraguti F, Bordi F,
Franz-Bacon K, Reggiani A, Matarese V, Conde´ F, Collingridge
GL, Cre´pe LF (1994) Motor deficit and impairment of synaptic
plasticity in mice lacking mGluR1. Nature 372:237–243.
Conti V, Aghaie A, Cilli M, Martin N, Caridi G, Musante L, Candiano G,
Castagna M, Fairen A, Ravazzolo R, Guenet JL, Puliti A (2006)
Crv4, a mouse model for human ataxia associated with kypho-
scoliosis caused by anmRNAsplicingmutation of themetabotropic
glutamate receptor 1 (Grm1). Int J Mol Med 18:593–600.
Cozzi A, Meli E, Carla` V, Pellicciari R, Moroni F, Pellegrini-Giampietro
DE (2002) Metabotropic glutamate 1 (mGlu1) receptor
antagonists enhance GABAergic neurotransmission: a
mechanism for the attenuation of post-ischemic injury and
epileptiform activity? Neuropharmacology 43:119–130.
De Vry J, Horva´th E, Schreiber R (2001) Neuroprotective and
behavioral effects of the selective metabotropic glutamate mGlu
(1) receptor antagonist BAY 36–7620. Eur J Pharmacol
428:203–214.
Dhingra A, Vardi N (2012) ‘‘mGlu Receptors in the Retina” – WIREs
Membrane Transport and Signaling. Wiley Interdiscip Rev Membr
Transp Signal 1:641–653.
Doumazane E, Scholler P, Zwier JM, Trinquet E, Rondard P, Pin JP
(2011) A new approach to analyze cell surface protein complexes
reveals specific hetero-dimeric metabotropic glutamate receptors.
FASEB J 25:66–77.
Feather-Schussler DN, Ferguson TS (2016) A battery of motor tests
in a neonatal mouse model of cerebral palsy. J Vis Exp: JoVE
117:53569.
Ferraguti F, Pietra C, Valerio E, Corti C, Chiamulera C, Conquet F
(1997) Evidence against a permissive role of the metabotropic
glutamate receptor 1 in acute excitotoxicity. Neuroscience 79:1–5.
Ferreira IL, Duarte CB, Carvalho AP (1996) Ca2+ influx through
glutamate receptor-associated channels in retina cells correlates
with neuronal cell death. Eur J Pharmacol 302:153–162.
Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic
NMDA receptor signalling: implications for neurodegenerative
disorders. Nat Rev Neurosci 11:682–696.
Herna´ndez C, Simo´ R (2012) Neuroprotection in diabetic retinopathy.
Curr Diabetes Rep 12:329–337.Hinton DR, Sadun AA, Blanks JC, Miller CA (1986) Optic-nerve
degeneration in Alzheimer’s disease. N Engl J Med 315:485–487.
Ichise T, Kano M, Hashimoto K, Yanagihara D, Nakao K, Shigemoto
R, Katsuki M, Aiba A (2000) MGluR1 in cerebellar Purkinje cells
essential for long-term depression, synapse elimination, and
motor coordination. Science 288:1832–1835.
Kano M, Watanabe T (2017) Type-1 metabotropic glutamate receptor
signaling in cerebellar Purkinje cells in health and disease. F1000
Res 6:416.
Kaur C, Foulds WS, Ling EA (2008) Hypoxia-ischemia and retinal
ganglion cell damage. Clin Ophthalmol 2:879–889.
Koulen P, Kuhn R, Wa¨ssle H, Brandsta¨tter JH (1997) Group I
metabotropic glutamate receptors mGluR1alpha and mGluR5a:
localization in both synaptic layers of the rat retina. J Neurosci
17:2200–2211.
Lavreysen H, Wouters R, Bischoff F, No´brega Pereira S, Langlois X,
Blokland S, Somers M, Dillen L, Lesage AS (2004) JNJ16259685,
a highly potent, selective and systemically active mGlu1 receptor
antagonist. Neuropharmacology 47:961–972.
Li H, Zhang N, Sun G, Ding S (2013) Inhibition of the group I mGluRs
reduces acute brain damage and improves long-term histological
outcomes after photothrombosis-induced ischaemia. ASN Neuro
5:195–207.
Lipton SA (2003) Possible role for memantine in protecting retinal
ganglion cells from glaucomatous damage. Surv Ophthalmol
1:38–46.
Lowe CU, Zavon MR, Olney JW, Sharpe LG (1970) Monosodium
glutamate: specific brain lesion questioned. Science
167:1016–1017.
Meli E, Picca R, Attucci S, Cozzi A, Peruginelli F, Moroni F, Pellegrini-
Giampietro DE (2002) Activation of mGlu1 but not mGlu5
metabotropic glutamate receptors contributes to postischemic
neuronal injury in vitro and in vivo. Pharmacol Biochem Behav
73:439–446.
Moroni F, Attucci S, Cozzi A, Meli E, Picca R, Scheideler MA,
Pellicciari R, Noe C, Sarichelou I, Pellegrini-Giampietro DE (2002)
The novel and systemically active metabotropic glutamate 1
(mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic
neuronal death. Neuropharmacology 42:741–751.
Murotomi K, Takagi N, Takayanagi G, Ono M, Takeo S, Tanonaka K
(2008) MGluR1 antagonist decreases tyrosine phosphorylation of
NMDA receptor and attenuates infarct size after transient focal
cerebral ischemia. J Neurochem 105:1625–1634.
Murotomi K, Takagi N, Mizutani R, Honda TA, Ono M, Takeo S,
Tanonaka K (2010) MGluR1 antagonist decreased NADPH
oxidase activity and superoxide production after transient focal
cerebral ischemia. J Neurochem 114:1711–1719.
Nadal-Nicola´s FM, Jime´nez-Lo´pez M, Sobrado-Calvo P, Nieto-Lo´pez
L, Ca´novas-Martı´nez I, Salinas-Navarro M, Vidal-Sanz M, Agudo
M (2009) Brn3a as a marker of retinal ganglion cells: qualitative
and quantitative time course studies in naive and optic nerve-
injured retinas. Invest Ophthalmol Vis Sci 50:3860–3868.
Nicoletti F, Bruno V, Catania MV, Battaglia G, Copani A, Barbagallo
G, Cen˜a V, Sanchez-Prieto J, Spano PF, Pizzi M (1999) Group-I
metabotropic glutamate receptors: hypotheses to explain their
dual role in neurotoxicity and neuroprotection.
Neuropharmacology 38:1477–1484.
Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F,
Schoepp DD, Wroblewski JT, Pin JP (2011) Metabotropic
glutamate receptors: from the workbench to the bedside.
Neuropharmacology 60:1017–1041.
Niwa M, Aoki H, Hirata A, Tomita H, Green PG, Hara A (2016) Retinal
cell degeneration in animal models. Int J Mol Sci 17(1).
Ohtani Y, Miyata M, Hashimoto K, Tabata T, Kishimoto Y, Fukaya M,
Kase D, Kassai H, Nakao K, Hirata T, Watanabe M, Kano M, Aiba
A (2014) The synaptic targeting of mGluR1 by its carboxyl-
terminal domain is crucial for cerebellar function. J Neurosci
34:2702–2712.
Olney JW (1969) Glutamate-induced retinal degeneration in neonatal
mice. Electron microscopy of the acutely evolving lesion. J
Neuropathol Exp Neurol 28:455–474.
F. Liberatore et al. / Neuroscience 363 (2017) 142–149 149Osborne NN (2009) Recent clinical findings with memantine should
not mean that the idea of neuroprotection in glaucoma is
abandoned. Acta Ophthalmol 87:450–454.
Pellegrini-Giampietro DE, Peruginelli F, Meli E, Cozzi A, Albani-
Torregrossa S, Pellicciari R, Moroni F (1999) Protection with
metabotropic glutamate 1 receptor antagonists in models of
ischemic neuronal death: time-course and mechanisms.
Neuropharmacology 38:1607–1619.
Pshenichkin S, Dolin´ska M, Klauzin´ska M, Luchenko V, Grajkowska
E, Wroblewski JT (2008) Dual neurotoxic and neuroprotective role
of metabotropic glutamate receptor 1 in conditions of trophic
deprivation – possible role as a dependence receptor.
Neuropharmacology 55:500–508.
Ra´cz B, Gallyas Jr F, Kiss P, Tama´s A, Lubics A, Lengva´ri I, Ro¨th E,
To´th G, Hegyi O, Verza´l Z, Fabricsek C, Reglo´di D (2007) Effects
of pituitary adenylate cyclase activating polypeptide (PACAP) on
the PKA-Bad-14-3-3 signaling pathway in glutamate-induced
retinal injury in neonatal rats. Neurotox Res 12:95–104.
Romano MR, Di Menna L, Scarselli P, Mascio G, Madonna M,
Notartomaso S, Puliti A, Bruno V, Battaglia G, Nicoletti F (2016)
Type-1, but not type-5, metabotropic glutamate receptors are
coupled to polyphosphoinositide hydrolysis in the retina.
Neurochem Res 41:924–932.
Seki M, Lipton SA (2008) Targeting excitotoxic/free radical signaling
pathways for therapeutic intervention in glaucoma. Prog Brain
Res 173:495–510.
S´miaowska M, Goembiowska K, Kajta M, Ziezba B, Dziubina A, Domin
H (2012) Selective mGluR1 antagonist EMQMCM inhibits thekainate-induced excitotoxicity in primary neuronal cultures and in
the rat hippocampus. Neurotox Res 21:379–392.
Tama´s A, Ga´briel R, Ra´cz B, De´nes V, Kiss P, Lubics A, Lengva´ri I,
Reglodi D (2004) Effects of pituitary adenylate cyclase activating
polypeptide in retinal degeneration induced by monosodium-
glutamate. Neurosci Lett 372:110–113.
Tenhula WN, Xu SZ, Madigan MC, Heller K, Freeman WR, Sadun AA
(1992) Morphometric comparisons of optic nerve axon loss in
acquired immunodeficiency syndrome. Am J Ophthalmol
113:14–20.
Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan
A, Aakalu VK, Lanahan AA, Sheng M, Worley PF (1999) Coupling
of mGluR/Homer and PSD-95 complexes by the Shank family of
postsynaptic density proteins. Neuron 23:583–592.
Valerio A, Ferrario M, Paterlini M, Liberini P, Moretto G, Cairns NJ,
Pizzi M, Spano P (2002) Spinal cord mGlu1a receptors: possible
target for amyotrophic lateral sclerosis therapy. Pharmacol
Biochem Behav 73:447–454.
Xu W, Wong TP, Chery N, Gaertner T, Wang YT, Baudry M (2007)
Calpain-mediated mGluR1alpha truncation: a key step in
excitotoxicity. Neuron 53:399–412.
Yang XL (2004) Characterization of receptors for glutamate and
GABA in retinal neurons. Prog Neurobiol 73:127–150.
Zhou M, Xu W, Liao G, Bi X, Baudry M (2009) Neuroprotection
against neonatal hypoxia/ischemia-induced cerebral cell death by
prevention of calpain-mediated mGluR1alpha truncation. Exp
Neurol 218:75–82.(Received 9 June 2017, Accepted 5 September 2017)
(Available online 14 September 2017)
